CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BMY

Phase 3

Development Phase

6

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Oct '27
BMYPhase 2

Nivolumab Phase 2 Est. Readout

Nivolumab
Oct 2027~
CT.gov
00%
Q2 '27
BMYPhase 2

Nivolumab Phase 2 Est. Readout

Nivolumab
Q2 2027~Q
CT.gov
00%
Mar '27
BMYPhase 3

Nivolumab Phase 3 Est. Readout

Nivolumab
Mar 2027~
CT.gov
00%
Feb '27
BMYPhase 2

Nivolumab Phase 2 Est. Readout

Nivolumab
Feb 2027~
CT.gov
00%
Jan '27
BMYPhase 2

Nivolumab Phase 2 Est. Readout

Nivolumab
Jan 2027~
CT.gov
00%
Dec '26
BMYPhase 2

Nivolumab Phase 2 Est. Readout

Nivolumab
Dec 2026~
CT.gov
00%
Competitive Landscape

0 competitors in Recurrent Head and Neck Squamous Cell Carcinoma

View Full Landscape
Drug Information

Target Indication

Recurrent Head and Neck Squamous Cell Carcinoma

Clinical Trial

NCT03521570

Last updated: 8/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.